Is Sonoma Pharmaceuticals Stock a Good Investment?
Sonoma Pharmaceuticals Investment Advice | SNOA |
- Examine Sonoma Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Sonoma Pharmaceuticals' leadership team and their track record. Good management can help Sonoma Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Sonoma Pharmaceuticals' business and its evolving consumer preferences.
- Compare Sonoma Pharmaceuticals' performance and market position to its competitors. Analyze how Sonoma Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Sonoma Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Sonoma Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Sonoma Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Sonoma Pharmaceuticals is a good investment.
Sell | Buy |
Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Sonoma Pharmaceuticals Stock
Researching Sonoma Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.41. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sonoma Pharmaceuticals recorded a loss per share of 0.82. The entity last dividend was issued on the 20th of June 2019. The firm had 1:9 split on the 20th of June 2019.
To determine if Sonoma Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sonoma Pharmaceuticals' research are outlined below:
| Sonoma Pharmaceuticals is way too risky over 90 days horizon | |
| Sonoma Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Sonoma Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Sonoma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 13.27 M. Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 4.48 M. | |
| Sonoma Pharmaceuticals currently holds about 5.59 M in cash with (6.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from techradar.com: Touchscreen MacBooks could launch in the next few years - but not before a significant iPad overhaul |
Sonoma Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sonoma Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sonoma Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 19th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of June 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Sonoma Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Sonoma Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-13 | 2023-09-30 | -0.24 | -0.29 | -0.05 | 20 | ||
2024-02-08 | 2023-12-31 | -0.21 | -0.08 | 0.13 | 61 | ||
2023-08-10 | 2023-06-30 | -0.12 | -0.2796 | -0.1596 | 133 | ||
2019-11-14 | 2019-09-30 | -1.18 | -0.91 | 0.27 | 22 | ||
2021-02-16 | 2020-12-31 | -0.72 | -0.32 | 0.4 | 55 | ||
2016-07-28 | 2016-06-30 | -4.95 | -5.49 | -0.54 | 10 | ||
2019-06-30 | 2019-03-31 | -2.12 | -1.52 | 0.6 | 28 | ||
2019-02-14 | 2018-12-31 | -3.01 | -2.34 | 0.67 | 22 |
Know Sonoma Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonoma Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonoma Pharmaceuticals backward and forwards among themselves. Sonoma Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Sonoma Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Wells Fargo & Co | 2023-12-31 | 105 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 86.0 | Hanson Mcclain Inc | 2023-12-31 | 65.0 | Bank Of America Corp | 2023-12-31 | 44.0 | Hbc Financial Services, Pllc | 2023-12-31 | 2.0 | Renaissance Technologies Corp | 2023-12-31 | 0.0 | Advisor Group Holdings, Inc. | 2023-12-31 | 0.0 | Two Sigma Securities, Llc | 2023-12-31 | 0.0 | Geode Capital Management, Llc | 2023-12-31 | 35.8 K | Jpmorgan Chase & Co | 2023-12-31 | 33 K | Hrt Financial Llc | 2023-12-31 | 27.9 K |
Sonoma Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.36 M.Market Cap |
|
Sonoma Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.29) | (0.30) | |
| Return On Capital Employed | (0.33) | (0.35) | |
| Return On Assets | (0.29) | (0.30) | |
| Return On Equity | (0.74) | (0.71) |
Determining Sonoma Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Sonoma Pharmaceuticals is a good buy. For example, gross profit margin measures Sonoma Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sonoma Pharmaceuticals' profitability and make more informed investment decisions.
The data published in Sonoma Pharmaceuticals' official financial statements typically reflect Sonoma Pharmaceuticals' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Sonoma Pharmaceuticals' quantitative information. For example, before you start analyzing numbers published by Sonoma accountants, it’s essential to understand Sonoma Pharmaceuticals' liquidity, profitability, and earnings quality within the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of Sonoma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sonoma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sonoma Pharmaceuticals' management manipulating its earnings.
Evaluate Sonoma Pharmaceuticals' management efficiency
Sonoma Pharmaceuticals has return on total asset (ROA) of (0.1944) % which means that it has lost $0.1944 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8287) %, meaning that it created substantial loss on money invested by shareholders. Sonoma Pharmaceuticals' management efficiency ratios could be used to measure how well Sonoma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of June 11, 2024, Return On Tangible Assets is expected to decline to -0.3. In addition to that, Return On Capital Employed is expected to decline to -0.35. At present, Sonoma Pharmaceuticals' Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Assets are forecasted to decline to about 15.2 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.70 | 2.57 | |
| Tangible Book Value Per Share | 2.70 | 2.57 | |
| Enterprise Value Over EBITDA | (0.07) | (0.08) | |
| Price Book Value Ratio | 0.38 | 0.39 | |
| Enterprise Value Multiple | (0.07) | (0.08) | |
| Price Fair Value | 0.38 | 0.39 | |
| Enterprise Value | 5.8 M | 5.5 M |
The analysis of Sonoma Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Sonoma Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Sonoma Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.37 |
Basic technical analysis of Sonoma Stock
As of the 11th of June 2024, Sonoma Pharmaceuticals has the Semi Deviation of 5.18, coefficient of variation of 1099.48, and Risk Adjusted Performance of 0.0656. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sonoma Pharmaceuticals, as well as the relationship between them.Sonoma Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonoma Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonoma Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonoma Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dal Poggetto John over a month ago Disposition of 1648 shares by Dal Poggetto John of Sonoma Pharmaceuticals at 175.5 subject to Rule 16b-3 | ||
Frederick Sandford over a month ago Acquisition by Frederick Sandford of 400000 shares of Sonoma Pharmaceuticals at 0.717 subject to Rule 16b-3 | ||
Bruce Thornton over three months ago Acquisition by Bruce Thornton of 60000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Bruce Thornton over six months ago Acquisition by Bruce Thornton of 100000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 |
Understand Sonoma Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Sonoma Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0656 | |||
| Market Risk Adjusted Performance | 0.677 | |||
| Mean Deviation | 5.78 | |||
| Semi Deviation | 5.18 | |||
| Downside Deviation | 8.96 | |||
| Coefficient Of Variation | 1099.48 | |||
| Standard Deviation | 10.83 | |||
| Variance | 117.32 | |||
| Information Ratio | 0.0899 | |||
| Jensen Alpha | 0.9735 | |||
| Total Risk Alpha | 0.9552 | |||
| Sortino Ratio | 0.1087 | |||
| Treynor Ratio | 0.667 | |||
| Maximum Drawdown | 85.9 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 14.29 | |||
| Downside Variance | 80.27 | |||
| Semi Variance | 26.84 | |||
| Expected Short fall | (12.91) | |||
| Skewness | 3.68 | |||
| Kurtosis | 21.01 |
| Risk Adjusted Performance | 0.0656 | |||
| Market Risk Adjusted Performance | 0.677 | |||
| Mean Deviation | 5.78 | |||
| Semi Deviation | 5.18 | |||
| Downside Deviation | 8.96 | |||
| Coefficient Of Variation | 1099.48 | |||
| Standard Deviation | 10.83 | |||
| Variance | 117.32 | |||
| Information Ratio | 0.0899 | |||
| Jensen Alpha | 0.9735 | |||
| Total Risk Alpha | 0.9552 | |||
| Sortino Ratio | 0.1087 | |||
| Treynor Ratio | 0.667 | |||
| Maximum Drawdown | 85.9 | |||
| Value At Risk | (11.11) | |||
| Potential Upside | 14.29 | |||
| Downside Variance | 80.27 | |||
| Semi Variance | 26.84 | |||
| Expected Short fall | (12.91) | |||
| Skewness | 3.68 | |||
| Kurtosis | 21.01 |
Consider Sonoma Pharmaceuticals' intraday indicators
Sonoma Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sonoma Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 0.2 | |||
| Day Typical Price | 0.2 | |||
| Price Action Indicator | (0.0005) | |||
| Period Momentum Indicator | (0.01) |
Sonoma Stock media impact
Far too much social signal, news, headlines, and media speculation about Sonoma Pharmaceuticals that are available to investors today. That information is available publicly through Sonoma media outlets and privately through word of mouth or via Sonoma internal channels. However, regardless of the origin, that massive amount of Sonoma data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Sonoma Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Sonoma Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Sonoma Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Sonoma Pharmaceuticals alpha.
Sonoma Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Sonoma Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sonoma Pharmaceuticals Corporate Management
| Jerome Dvonch | Interim Officer | Profile | |
| John Poggetto | Controller | Profile | |
| Victoria Covel | Assistant Controller | Profile | |
| Chad White | Interim Officer | Profile |
Additional Information and Resources on Investing in Sonoma Stock
When determining whether Sonoma Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sonoma Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sonoma Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sonoma Pharmaceuticals Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.82) | Revenue Per Share 1.946 | Quarterly Revenue Growth 0.066 | Return On Assets (0.19) | Return On Equity (0.83) |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Sonoma Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.